Project description DEENESFRITPL Smartphone-based apps for the detection of cardiovascular diseases Cardiovascular diseases cause millions of deaths annually. More than 80 % of these deaths are due to heart attack and stroke. The EU-funded CARDIOSIGNAL project will develop a suite of smartphone applications to detect heart conditions and save lives. The breakthrough technology will be able to identify atrial fibrillation (AFib), heart failure (HF) and coronary artery disease (CAD) without additional hardware. It will use a smartphone's gyroscope and accelerometer to measure heart activity by placing the smartphone on the user's chest for 60 seconds. The data is analysed in the cloud and results in a diagnosis. The applications for AFib detection are completed and clinically proven. The current project involves the development of applications for HF and CAD, with regulatory approval and launches across the EU, US and China to follow. Show the project objective Hide the project objective Objective CardioSignal is a suite of breakthrough smartphone apps to detect heart conditions and save lives. It will be the first technology to identify atrial fibrillation (AFib), heart failure (HF) and coronary artery disease (CAD) - all without extra hardware.Using CardioSignal, people at risk of serious cardiac conditions and their doctors can monitor their heart function quickly and at low cost. The app measures chest vibrations and analyses data in the cloud. Patients with abnormalities are directed to immediate medical attention.It outperforms Apple Watch, which cannot accurately detect AFib and is incapable of detecting CAD & HF.Context: 49 million Europeans suffer from cardiovascular conditions annually, resulting in heart attacks and stroke. Early detection and follow-up could save millions of lives.Solution: CardioSignal apps use a smartphone's gyroscope and accelerometer to measure heart activity across six parameters. Users place the smartphone on their chest for 60 seconds. The cloud-based platform analyses data and returns a diagnosis.Business Model: (1) HF & CAD: B2B sales to private healthcare companies, big pharma, diagnostics firms. Pharma companies Roche and Novartis are ready to conduct trials, leading to major contracts. (2) AFib: B2B2C sales.Market Opportunity: 300M potential users in EU, 1B globally. €4.2B TAM in target countries.Company: Precordior Oy, a medtech spin-off from University of Turku, Finland. Team of 13 highly experienced cardiologists, technologists and sales experts. €3M in funding secured, ready to grow.Progress: V1 app for AFib detection complete, clinically proven. 19 patents secured. EU Seal of Excellence.Project: Develop new apps for HF and CAD. Obtain regulatory approval. Launch across EU; US and China to follow.Impact by 2025: 1.27M at-risk patients and doctors using app daily in EU, USA and China. €85M revenue, €38M EBITDA, 250 FTE. Fields of science social scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesclinical medicinecardiologycardiovascular diseasesengineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phonesmedical and health sciencesbasic medicineneurologystroke Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2b - SME Instrument (grant only and blended finance) Coordinator PRECORDIOR OY Net EU contribution € 1 962 625,00 Address Aurakatu 6 20100 Turku Finland See on map Region Manner-Suomi Etelä-Suomi Varsinais-Suomi Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 841 125,00